Drugs / ALETA-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06045910 | Feb 2024 → Feb 2028 expected | diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma | Cancer Research UK | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | Aleta BioTherapeutics | Results Aleta & Cancer Research UK Announce Promising Phase I/II Data from ALETA-001 Clinical Trial for Patients w/ Relapsed/Refractory B-Cell Malignancies Previously Treated with CD19 CAR T-Cell Therapy aletabio.com ↗ |
| 2023-08-08 | Aleta BioTherapeutics | Regulatory Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 aletabio.com ↗ |
| 2023-05-11 | Aleta BioTherapeutics | Results ALETA-001, a CAR-T Engager protein, or CTE, optimizes anti-CD19 CAR-T celltherapies for lymphoma aletabio.com ↗ |
| 2022-11-07 | Aleta BioTherapeutics | Regulatory Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 aletabio.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALETA-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06045910 ↗ |
| Modality | Protein / enzyme biologic | “a novel chimeric antigen receptor (CAR) T-cell engager” NCT06045910 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT06045910 ↗ |